Efforts to curb the latest Ebola outbreak in the Democratic Republic of Congo are being bolstered by clinical trials for a vaccine targeting the less common Bundibugyo strain, which has been identified in recent cases. Health officials are racing to deploy the experimental vaccine as part of broader containment measures, including surveillance and treatment centers, amid concerns over the strain’s potential to spread. The trials mark a critical step in expanding Ebola response tools beyond the more widely studied Sudan and Zaire strains. With transmission ongoing, the vaccine’s development could offer a vital new defense in the fight against the deadly virus.
Trials for a vaccine for the Bundibugyo strain are ongoing as DRC authorities try to control the Ebola outbreak.
